2022
Breast Cancer Subtypes and Incidence of Brain Metastases in the SEER Database
Kinslow C, Knisely J, Cheng S, Connolly E, Wang T, Yu J. Breast Cancer Subtypes and Incidence of Brain Metastases in the SEER Database. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e6. DOI: 10.1016/j.ijrobp.2022.07.685.Peer-Reviewed Original ResearchMetachronous brain metastasesSynchronous brain metastasesBreast cancer subtypesIncidence of brain metastasesBrain metastasesBreast cancerCancer subtypesTNBC patientsBreast cancer diagnosisFrequency of brain metastasesPresence of brain metastasesPrevalence of brain metastasesHER2+ breast cancerTime of initial diagnosisSubtypes of breast cancerIncreasing proportion of patientsOccult brain metastasesSEER-18 databaseBrain metastasis diagnosisMetastatic breast cancerProportion of patientsFrequency of subtypesBreast cancer patientsCancer diagnosisIdentifier numberHospital Frailty Risk Score and healthcare resource utilization after surgery for metastatic spinal column tumors.
Elsamadicy AA, Koo AB, Reeves BC, Pennington Z, Yu J, Goodwin CR, Kolb L, Laurans M, Lo SL, Shin JH, Sciubba DM. Hospital Frailty Risk Score and healthcare resource utilization after surgery for metastatic spinal column tumors. Journal Of Neurosurgery Spine 2022, 37: 241-251. PMID: 35148505, DOI: 10.3171/2022.1.spine21987.Peer-Reviewed Original ResearchHospital Frailty Risk ScoreLength of staySpinal column tumorsFrailty Risk ScoreNonroutine dischargeHospital admissionHigh frailtyIntermediate frailtyDischarge dispositionSpinal tumorsLower frailtyDiagnostic codesRisk scoreHigher total hospital costsMean LOSNational Inpatient Sample databaseMultivariate logistic regression analysisICD-10 diagnostic codesImpact of frailtyRetrospective cohort studyHealthcare resource utilizationProportion of patientsTotal hospital costsProcedural Coding SystemLogistic regression analysis
2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakePost-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques
Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer 2021, 161: 171-179. PMID: 34607209, DOI: 10.1016/j.lungcan.2021.09.010.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyNon-small cell lung cancerCell lung cancerRadiation therapyPropensity-score matchingLA-NSCLCCardiac toxicityLung cancerAdvanced non-small cell lung cancerClinical risk factorsProportion of patientsMultivariable logistic regressionPrior treatment historyPredictors of receiptUse of IMRTConformal radiation therapyLong-term toxicityChi-squared testRadiation therapy techniquesRadiotherapy treatment techniquesUpfront surgeryElderly patientsTreatment toxicityMean ageMedicare database
2020
The Association Between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer.
Hsiang W, Han X, Jemal A, Nguyen KA, Shuch B, Park H, Yu JB, Gross CP, Davidoff AJ, Leapman MS. The Association Between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer. Urology Practice 2020, 7: 252-258. PMID: 34017908, PMCID: PMC8130174, DOI: 10.1097/upj.0000000000000109.Peer-Reviewed Original ResearchGerm cell tumorsTesticular germ cell tumorsProportion of patientsAffordable Care ActNon-expansion statesNational Cancer Data BaseExpansion statusState Medicaid expansion statusTesticular cancer patientsAdvanced-stage cancerLate-stage diagnosisLow-income patientsHealth insuranceCare ActMedicaid expansion statesMedicaid expansion statusDisease stageCancer patientsInsurance statusTesticular cancerCell tumorsPost-ACAMedicaid coveragePatientsMedicaid expansionPembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria
2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)
Patrice G, Lester-Coll N, Yu J, Amdahl J, Delea T, Patrice S. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 97-106. PMID: 29029885, DOI: 10.1016/j.ijrobp.2017.08.041.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerThoracic radiation therapyProgression-free survivalIncremental cost-effectiveness ratioExtensive-stage small cell lung cancer patientsSmall cell lung cancerCell lung cancerStandard treatmentLung cancer trialsRadiation therapyOverall survivalLung cancerUS health care payer perspectiveLong-term survival benefitCancer trialsFavorable incremental cost-effectiveness ratiosProgressive metastatic diseaseHealth care payer perspectiveProportion of patientsBase-case analysisFollow-up intervalCost-effectiveness ratioMetastatic diseasePostprogression survivalPayer perspective